Company: bluebird bio
Job title: Director, Value Demonstration, Market Access
Meghan Gallagher is a health economist, currently with bluebird bio. At bluebird she is responsible for leading the health economics strategy and evidence generation for the sickle cell disease gene therapy program. Meghan has nearly 15 years’ experience working as a health economist, predominantly for the biopharmaceutical industry. Her interests include novel economic modeling approaches including extended cost-effectiveness analysis, health economics in emerging markets, specifically the Middle East and Africa region, and macroeconomic consequences of healthcare innovation. Meghan completed her undergraduate training in economics at The American University in Washington, DC, USA and her advanced training in pharmacoeconomics at SDA Bocconi University in Milan, Italy. She is an avid international traveler with a curiosity for culture and people, nature and wildlife, and too many cuisines to mention. She resides with her husband just outside Boston, Massachusetts.
Evaluating the Unique Opportunities in the Blood Disease Space 9:30 am
Utilizing real-world data to assess unmet need in the gene therapy landscape Developing novel economic models to understand product value and opportunityRead more
day: Day Two